达可替尼与吉非替尼一线治疗EGFR Exon19/21突变型晚期非小细胞肺癌的疗效对比  

Comparison of the Efficacy of Dakotinib and Gefitinib in First-line Treatment of EGFR Exon19/21 Mutant Advanced Non-small Cell Lung Cancer

作　　者：康鹤耀 何凌[1] 王瑞[1] KANG Heyao;HE Ling;WANG Rui(Luohe Central Hospital,Luohe,462000)

机构地区：[1]河南省漯河市中心医院,462000

出　　处：《实用癌症杂志》2024年第10期1675-1679,共5页The Practical Journal of Cancer

摘　　要：目的对比达可替尼与吉非替尼一线治疗EGFR Exon19/21突变型晚期非小细胞肺癌的疗效。方法收集108例表皮生长因子受体(epidermal growth factor receptor,EGER)突变型晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者资料,依据治疗方法的不同将患者分为2组,达可替尼组58例,吉非替尼50例。统计2组疗效。结果2组基线特征比较差异均无统计学意义(P>0.05)。达可替尼组与吉非替尼组近期疗效比较,差异均无统计学意义(P>0.05)。随访截止2023年6月,2组患者均完成随访,无脱落病例。达可替尼组中位PFS长于吉非替尼组(12.6 vs 8.5个月,χ^(2)=34.009,P<0.001)。达可替尼组患者中位OS为23.1个月,吉非替尼组患者中位OS为16.3个月,2组间OS差异无统计学意义(χ^(2)=2.123,P=0.158)。2组患者不良反应发生情况比较,差异均无统计学意义(P<0.05),但是达可替尼组Ⅰ度、Ⅱ度胃肠道反应以及Ⅲ度、Ⅳ度痤疮发生率略高。结论达可替尼与吉非替尼一线治疗EGFR Exon19/21突变型晚期非小细胞肺癌的疗效相似,但是达可替尼组PFS更具优势,而吉非替尼相较达可替尼安全性略高。Objective To compare the efficacy of dacotinib and gefitinib in first-line treatment of EGFR Exon19/21 mutant advanced non-small cell lung cancer.Methods Data of 108 patients with Epidermal Growth Factor Receptor(EGER)mutant advanced Non-Small Cell Lung Cancer(NSCLC)were collected and divided into 2 groups according to different treatment methods.There were 58 cases in dacotinib group and 50 cases in gefitinib group.The curative effect of the 2 groups was analyzed.Results There was no significant difference in baseline characteristics between the 2 groups(P>0.05).There was no significant difference in short-term efficacy between the dacotinib group and gefitinib group(P>0.05).Follow-up was completed until June 2023,and no cases of abscission were reported in both groups.The median PFS in dacotinib group was longer than that in gefitinib group(12.6 vs 8.5 months,χ^(2)=34.009,P<0.001).The median OS was 23.1 months in the Dakotinib group and 16.3 months in the gefitinib group,with no significant difference between the 2groups(χ^(2)=2.123,P=0.158).There was no statistical significance in the occurrence of adverse reactions between the two groups(P<0.05),but the incidence of gradeⅠandⅡgastrointestinal reactions and the incidence of gradeⅢandⅣacne was slightly higher.Conclusions The efficacy of Dakotinib and gefitinib in first-line treatment of EGFR Exon19/21 advanced non-small cell lung cancer is similar,but the PFS of the Dakotinib group is more superior,and gefitinib is slightly safer than Dakotinib.

关 键 词：达可替尼 吉非替尼 EGFR Exon19/21突变型 晚期非小细胞肺癌 安全性 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]